AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

31 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

26 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

25 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

20 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Amarin Appoints Patrick Holt as President and Chief Executive Officer

18 Jul 2023 15:16:00 By Nasdaq GlobeNewswire

Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

18 Jul 2023 15:15:00 By Nasdaq GlobeNewswire

Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

21 Jun 2023 08:00:54 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

01 Jun 2023 15:30:00 By Nasdaq GlobeNewswire

Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China

01 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

12 May 2023 10:00:00 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

03 May 2023 06:00:01 By Nasdaq GlobeNewswire

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

19 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

17 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Announces Board Departures

06 Mar 2023 15:05:43 By Nasdaq GlobeNewswire

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

06 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

05 Mar 2023 09:21:00 By Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 Mar 2023 06:00:01 By Nasdaq GlobeNewswire

Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders

28 Feb 2023 09:38:06 By Nasdaq GlobeNewswire